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rAbstract
Synthetic biology is a series of scientific and technological practices involved in the
application of engineering principles to the design and production of predictable
and robust biological systems. While policy discussions abound in this area,
emerging technologies like synthetic biology present considerable challenges in the
articulation of concrete policy options given that their introduction into society may
still be in the distant future. This paper reports on a series of governance workshops
that focused on synthetic biology’s ethical, legal, and social implications (ELSI) as
they pertain to human health, and discusses particular limitations of the ELSI
approach that we encountered in our work. In an attempt to avoid policymaking for
potential implications of uncertain future applications we instead conclude by
proposing tangible forms of anticipatory governance that may be more adequate in
addressing the more immediate concerns raised by synthetic biology.
Keywords: Synthetic biology; ELSI; Governmental regulation; Anticipatory
governance; Responsible research and innovationIntroduction: Synthetic biology, and its ethical, legal and social implications
In this article we want to share our experiences with policy-oriented work that was
undertaken in the context of EU-funded research that has come to typify ELSI ap-
proaches to the life-sciences. These experiences were gained over the course of a
three-year European (FP7 Science in Society) project Synthetic Biology for Human
Health – The Ethical and Legal Issues (SYBHEL). It was our original task in this pro-
ject to add to the existing policy literature on synthetic biology (SynBio) by exploring
the governance implications of the ethical, legal, and social issues arising from potential
future applications of SynBio in the field of human health. However, in trying to
complete this task we faced a number of challenges that made us reflect on the aims of
current forms of ELSI scholarship on new and emerging technologies like SynBio. As
we will show in this article, the main findings of our work in the SYBHEL project also
prompted us to reconsider the traditional aims of doing ELSI research.
SynBio is an emerging field that combines molecular biology, engineering, biochem-
istry, computer sciences, and other disciplines into new practices of biological design
that are both diverse in their approaches and full of hope and promise. While SynBio
can be seen as a collection of activities rather than a distinct, singular, or totally novel
practice, some of its proponents claim that such activities stand to revolutionize our
mode of industrial production through the assemblage of multipurpose micro-organisms,2014 Douglas and Stemerding; licensee Springer. This is an Open Access article distributed under the terms of the Creative
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(Carlson 2007; Singh 2011). In debates about the novelty of SynBio, some define it as
an extension of earlier practices in genetic engineering. Others argue that those earlier
practices could rather be seen as genetic modification; whereas current activities really
and truly aim to apply engineering principles of predictability, reliability, control, and
abstraction to the construction of various kinds of biological systems (Tucker and
Zilinskas 2006; O’Malley et al. 2008). However, these visions generally agree on the
expectation that SynBio, in adopting engineering principles, may foster new options
for bio-based innovation in materials, energy, food, environmental remediation, and
medicine (Lowerie and Tait 2010; Cichocka et al. 2011).
These visions of SynBio have also given rise to a wider debate about its societal implica-
tions. Over the past ten years this debate has led to a flurry of activity – particularly in
Europe – on science policy analysis in the form of reports and opinions by ethical com-
mittees, learned societies, as well as governmental and nongovernmental organizations
(Stemerding and Rerimassie 2013). To date these policy discussions have tended to focus
on SynBio in general and to a series of ethical, legal and social issues that have come to
characterize a kind of ‘ELSI scholarship’ on new and emerging technologies (Calvert and
Martin 2009; Rabinow and Bennet 2009 and Rabinow and Bennett 2012). Typically these
reports and opinions start with a definition of SynBio and its related techniques and tech-
nologies, and then provide a series of potential applications that are envisaged across a
number of different sectors, which are subsequently contrasted against concerns about
possible risks and implications. Predominantly these issues take the form of biosafety and
biosecurity risks relating to the accidental and purposeful release of SynBio products, the
role of intellectual property regimes and patenting in securing or hindering a fair develop-
ment of SynBio, and wider issues of ethical and public acceptability raised by the engineer-
ing ambitions of SynBio.
As a research activity which focused on the ethical and legal implications of potential
future applications of SynBio for human health, SYBHEL was designed and funded as
a typical ELSI project. However, over the course of our work we found that this ELSI
approach was not particularly amenable to the formulation of actionable policy recom-
mendations to the European Commission. This was in part due to the future-
orientated nature of SynBio’s applications, which are highly uncertain. As a result, our
policy-orientated ELSI research was being founded on scientific speculations about
the great potential of future technologies, and on this basis engaging in ‘speculative
ethics’ (Nordmann 2007). Moreover, by focusing on the ‘downstream’ implications of
potential future developments that are envisaged for SynBio we found that we were
taking for granted current practices and developments actually on-going in the early
phases of the emerging fields. Thus, working in a typical ‘ELSI-mode’, we were con-
fined to following the science rather than engaging ourselves in issues of science and
technology policy making.
In the following we will show how our experiences in the SYBHEL project involved
us in an important challenge: bridging the gap between innovation and ELSI by paying
attention to ongoing developments in research and innovation (Rip and van Lente
2013). In this way, our work also demonstrates a development noted by Chadwick and
Zwart in their introductory editorial to Life Sciences, Society and Policy, involving a shift
from ELSI – as research focusing on ethical, legal and social implications – to a form
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reflections and deliberations an integrated part of their work’ (Chadwick and Zwart 2013:
2–3). We conclude the paper by proposing tangible forms of anticipatory governance that
may be more adequate in addressing the more immediate concerns raised by SynBio.Synthetic biology and human health – ethical and legal issues: The SYBHEL
project
Our aim to address the policy implications of the ethical, legal, and social issues that
might arise from future SynBio health applications was defined by a specific policy
work-package within the SYBHEL project. Our task was to synthesize the findings of
the other SYBHEL work-packages that explored the ethical and legal issues pertaining
to SynBio’s health applications, and place them in a policy-relevant context. In ap-
proaching this task we asked descriptive questions about the kind of SynBio health
applications that are envisioned in the field, the possible ethical and legal issues
related to those applications, and the governance tools available for addressing these
questions in the context of European health policy making. In doing so, our approach
was inspired by the above-mentioned reports and opinions on SynBio more generally,
and can broadly be seen as following the ELSI mode that has come to characterize
much of the policy work on new and emerging technologies.
In order to explore and understand the manner by which SynBio and governance
could interact in a meaningful way to achieve (public) health goals, we organized two
expert workshops, one focusing on the European context, the other on a global health
context (Douglas and Stemerding 2011, Douglas and Stemerding 2012, Douglas and
Stemerding 2013a and b). The European Policy Workshop was held in Brussels in
March of 2011 with 20 participants that included policymakers and analysts, regulators,
members of ethics committees, academics in the social science and philosophy of Syn-
Bio, patient organizations, SynBio researchers, and members of the SYBHEL project.
The Global Health Workshop was held in The Hague in February of 2012, and included
25 participants ranging from representatives from international health organizations
and non-governmental organizations, research funders, SynBio practitioners and Do-It-
Yourself (DIY) biologists, regulators and biosafety experts, as well as academics in the
social science and philosophy of SynBio, and members of the SYBHEL project. These
workshops were structured around discussion papers we circulated in advance of the
workshop meetings. In these preparatory papers we outlined the possible applications
in human health resulting from SynBio, and described the principal governance mecha-
nisms that might be deployed in dealing with the ethical, legal, social and philosophical
issues emerging from those applications. In the following discussion of our SYBHEL
experiences the initial focus will be on the European Policy Workshop. However, in the
presentation of our findings and recommendations resulting from the SYBHEL project,
we will also include findings from the Global Health Workshop and from other work
packages in the project.
In preparing for the European Policy Workshop, we saw it as our first task to examine
a series of reports and articles that identified a variety of potentially promising applica-
tions of SynBio in the field of biomedicine and health (NEST High-Level Expert Group
2005; European Group on Ethics of Science and Technology 2009; OECD and The
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Bioethical Issues 2010; European Academies Science Advisory Council 2010). Based on
these documents, prospective future applications could be clustered into a few main
areas of application: new pharmaceutical production processes, new kinds of thera-
peutic and diagnostic products, new forms of targeted delivery, and new options for the
development of pharmaceutical products (see Table 1).
With a general overview of the potentially relevant health applications of SynBio in
place we moved to identify the specific ethical and legal issues that might be raised by
these applications. These issues were drawn from our own review of the existing policy
work in this area (Balmer and Martin 2008; European Group on Ethics of Science and
Technology 2009; Royal Academy of Engineering 2009; Rodemeyer 2009; DG 2010;
European Academies Science Advisory Council 2010; European Technology Assess-
ment Group and The Rathenau Instituut 2010; Lowerie and Tait 2010; Presidential
Commission for the Study of Bioethical Issues 2010; Zhang et al. 2011), and were based
on the workshop reports of our project partners relating to different philosophical and
public understandings of ‘life’ (Deplazes-Zemp 2010 and Deplazes-Zemp 2011), ways in
which future advances in SynBio might influence or alter concepts of health, disease,
therapy and suffering (Calladine et al. 2010; Szebik 2010; Bradshaw-Martin 2012), and
the extent to which current (biotechnology) patent regimes will be constraining or
enabling to future SynBio innovation for human health (de Miguel Beriain 2011 and de
Miguel Beriain 2012).
To assist us in asking questions about the relationship between SynBio’s prospective
health applications and its ELSI issues – as identified from the above sources – we
constructed the below Table 2. There the rows refer to the types of SynBio applications
identified in Table 1, and the columns reference the general ELSI issues identified in
the existing policy work on SynBio. It was not our intention to limit consideration
to the kind of ELSI issues that we identified from the existing policy work on SynBio
and from our project partners – hence the inclusion of the ‘other?’ category – nor
was it our suggestion that one issue applies to only one kind of application. Instead
of acting as a rigid analytical framework, these tables were presented as heuristic de-
vices to promote reflection on the relationship between future applications, issues,
and their implications for governance. For the use of tables in this regard we took
inspiration from the ‘5P governance’ heuristic devised by Alexander Kelle, whoTable 1 Potential health applications of synthetic biology
Types of application Example
New pharmaceutical
production processes
Synthesis of natural bioactive compounds (Neumann and Neumann-Staublitz
2010), such as artemisinin (Chang and Keasling 2006; Kizer et al. 2008; Newman
et al. 2006; Ro et al. 2006)
New kinds of therapeutic
products
Engineered viruses and bacteria (Lu and Collins 2009; Forbes 2010)
New kinds of diagnostic
products
Biosensors or improved immunoassay (Burbelo et al., 2010)
New forms of targeted
delivery
Bacteria engineered to invade cancer cells (Anderson et al. 2006)
Development of
pharmaceutical products
Synthetically attenuated virus for new vaccines (Coleman et al. 2008)
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SynBio (Kelle 2009: 88).
On the basis of the prospective health applications for SynBio -together with some of
the potential ethical, legal, and social issues that they might raise- in the European Pol-
icy Workshop we hoped to explore various governance approaches as mechanisms that
should enable the balancing of possible SynBio benefits vis-à-vis its possible risks and
implications. Accordingly, we sought to map these issues on the existing framework of
EU policy making, and thereby identify any possible gaps between existing EU govern-
ance and SynBio ELSI issues. There are a number of different governance mechanisms
available within the European context to address some of the ethical, legal and social is-
sues pertaining to SynBio’s health applications that range from hard laws (i.e. directives
and regulations) to soft laws (i.e. codes of conduct, ethical review, and public engage-
ment), which have been listed in the columns of Table 3. We offered this table as a
heuristic aide in our thinking on the ELSI issues listed in the row of Table 3, which
map on to those in Table 2.Table 3 The governance landscape for synthetic biology health application
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was: How well do these forms of governance match-up to these ELSI issues? More
specifically the following questions were being addressed during the workshop:
 What are the most prominent developments of SynBio likely to make an impact in
the area of health in the nearest possible future?
 What are some of the social, ethical, and legal considerations resulting from these
SynBio applications in health?
 What tools in the framework of European regulation, governance, and public
debate are available to deal with these social, ethical, and legal considerations?
 And following on from that, how can we address these social, ethical, and legal
considerations in the European governance framework, and what are the likely
outcomes of these social, ethical, and legal challenges for EU health policy?Experiences from the European policy workshop: limitations of the ELSI
approach
In spite of our preparatory work and use of heuristic devices, our approach and experi-
ences in ‘doing ELSI governance’ did not meet our expectations. Largely this was due
to the fact that the future developments that we took as a starting point (in Table 1) re-
late to potential health applications that are highly uncertain and are likely to appear in
society and on the market only in a future time span of decades. As an emerging plat-
form technology SynBio may enable a variety of future health applications, but we sim-
ply do not yet know where exactly it will lead us, if indeed the promissory visions of its
proponents will come to fruition. Thus, during the European Policy Workshop, it
remained a difficult and open question how to connect (in Table 2) in meaningful ways
these highly uncertain and speculative future visions for SynBio to the variety of ELSI
issuesa. Arguably, these general ELSI issues are not particular to SynBio, but refer to
broader developments and future visions we are already familiar with from other fields
of (bio) technology. In this situation of uncertainty and indeterminacy, we were never
really in the position to systematically gauge (in Table 3) the appropriateness of avail-
able governance tools for dealing with the future implications of SynBio for human
health. Our task of providing meaningful direction for policymakers consequently
seemed challenging and severely limited.
Our European Policy Workshop was not only instructive in showing the limitations of
this ELSI approach, it also made us think about issues of more immediate concern for
policy making in the field of SynBio and human health. Main issues of concern that
emerged from the workshop discussions were on the one hand related to governmental
challenges of SynBio regulation, and on the other hand to challenges of anticipatory
governance of SynBio innovation. In regard to policies of regulation there were discus-
sions about new challenges and needs for supplementary or advanced risk assessment
in SynBio, but there were also concerns voiced about the ways in which current re-
gimes of regulation may stifle potentially promising prospects for innovation. In other
words, regulation was discussed in the workshop not with respect to prospective future
impacts of SynBio, but as part of an ongoing co-evolution of science, technology and
society. Another important topic emphasized by workshop participants was the need
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both science and society in SynBio innovation. From this perspective the question be-
comes how to modulate ongoing processes of co-evolution by identifying strategic and
meaningful choices in the field (Rip 2009). As we learned from our Global Health
Workshop, the future of SynBio should not only be considered as a series of potential
(health) applications, but also as a series of platform technologies which may enable
different trajectories of research and innovation (Douglas and Stemerding 2013b).
Although it was our initial intention in the SYBHEL project to discuss the ‘down-
stream’ implications of future developments in SynBio, the actual workshop discussions
made us particularly aware of developments and challenges emerging more ‘upstream’
in the field. As policy analysts we were facing a new and emerging science which is still
in an early stage of research and development, and one that is characterized by future
uncertainties. Thus, we appropriately decided to steer away in our analysis and policy
recommendations from future consequences as our main concern, and instead moved
towards more immediate issues relating to current practices and experiences in the
field of SynBio and (global) health. In the following we will discuss in more detail our
main findings and recommendations based on observations and lessons from both our
workshops and from the other SYBHEL work-packages. With these recommendations
we want to contribute to a European policy agenda which combines adaptive forms of
government regulation (‘hard law’) with forms of anticipatory governance (‘soft law’) in
ways that encourage the commitment of both science and society to responsible re-
search and innovation in SynBio, acknowledging potential risks without prematurely
cutting off developments with potentially significant future (health) benefits.Findings and recommendations concerning governmental SynBio regulation
Irrespective of the limitations of our ELSI approach and our initial workshop agenda, the
events that we organized did produce inspiring discussions, presentations, and papers. In
doing so the workshops helped to open-up SynBio to a wider range of actors and concerns
thereby assisting us to translate these concerns into policy recommendations. An import-
ant theme arising from the interactions in the European Policy Workshop related to the
role and limitations of current European GMO safety legislation and medicinal product
regulations as they pertain to future health related developments in the field of SynBio.
This theme had been previously highlighted by the European Group on Ethics of Science
and Technology (EGE) in their official opinion on SynBio (European Group on Ethics of
Science and Technology 2009), and we were lucky enough to have three representatives
from the EGE in the European Policy workshop. In their report the EGE recommended
that the European Commission “should review the legislation applicable to synthetic biol-
ogy and assess its relevance to address the issues raised by synthetic biology” (2009: 53).
In our European Policy Workshop several issues were identified as being of special concern
in the context of SynBio and human health, from which we derived a number of recom-
mendations that are summarized in Table 4 and will be described in more detail below.GMO safety regulation
As the EGE pointed out in its opinion, the aim of SynBio is to produce “organisms with
multiple traits from multiple organisms, and therefore it may be difficult to predict
Table 4 Findings and recommendations concerning governmental SynBio regulation
Area of regulation Recommendation
GMO safety regulation There is a need for dedicated investments in the development of risk
assessment methods that match SynBio developments involving the
construction of cells with multiple new traits and the introduction of
engineered cells or viruses in the human body.
There is a need to find a new and careful balance within the current system
of GMO regulation so that it works to, on the one hand, facilitate innovation
and, on the other hand, to prioritize new emerging issues of risk assessment.
Regulation of medicinal
products and devices
There is a need to reconsider the current distinction between
pharmaceuticals and devices in the process of medical product approval in
Europe.
There is a need to consider a more transparent process of ethical review, in
which the results of research ethics evaluations are not only fed back to
individual projects (as is the current practice within DG Research and
Innovation), but to wider communities of researchers, patients, ethicists and
social scientists.
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develops not only engineered bacteria or viruses, but also engineered cells for intro-
duction into humans. As one of the EGE representatives participating in the European
Policy Workshop noted: the current GM risk assessment paradigm operates on the as-
sumption that small genetic modifications will not significantly affect the characteris-
tics of the host organism. However, given the level of complexity in cell engineering
and signalling between cells, small changes could have massive ramifications in the
human body. As a result serious questions were raised as to whether the current GM
risk assessment paradigm is suitable for application in the arena of SynBio and human
health. Participants in the European Policy workshop all agreed that there is a need for
dedicated investments in the development of risk assessment methods that match
SynBio developments involving the construction of cells with multiple new traits and
the introduction of engineered cells or viruses in the human body.
To be sure new risk management approaches should not be considered in isolation, and
discussions took place in other SYBHEL workshops about the need to include regulatory
safety concerns in practices of design (Bedau 2011 and Bedau 2012; Deplazes-Zemp
2011). For example, governmental regulations could be used to require the inclusion of a
genetic construct preventing uncontrolled reproduction of any engineered organism that
could be released into the environment – purposely or otherwise. Prohibiting the approval
of any organism that could multiply uncontrollably could work to encourage the kinds of
modelling and a design solution proposed by Bedau and others, and represents one way of
taking advantage of regulatory and technological co-production that is common in the area
of health and medicine (Faulkner 2009).
The need for more advanced forms of risk assessment and safety oriented design ap-
proaches should however be matched to another concern expressed in the SYBHEL
discussions, which relates to the impact on innovation of the current system of GMO
regulation. European GMO regulation has developed into a system which is very de-
manding and costly for innovators in the field, to such an extent that (especially small)
innovators may lose interest to pursue potentially promising product developments
based on genetic engineering. Maintaining the current system of GMO regulation may
thus discourage future SynBio innovation, nipping in the bud promising (health) appli-
cations with potential benefits for society, or pushing SynBio research out of the area
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From this point of view, European policymaking is at the crossroads for reconsidering the
architecture of the current regulatory system. In other words, our workshop participants
concluded that there is a need to find a new and careful balance within the current system
of GMO regulation so that it works to, on the one hand, facilitate innovation and, on the
other hand, prioritize new emerging issues of risk assessment.Regulation of medicinal products and devices
During our European Policy Workshop a representative of the European Medicines
Agency (EMA) highlighted the shift that is taking place to biologically-derived medi-
cinal product development, that is, to products based on compounds and cells derived
from the human body instead of the conventional chemically-derived compounds that
have come to characterize the pharmaceutical industry’s product line. These biologically-
derived products create new challenges for the assessment and market approval of medi-
cinal products, which is why particular categories of these products (e.g. gene therapy, cell
therapy, and tissue engineering) have been brought into Europe under a special regulatory
regime for advanced therapy medicinal products (ATMPs). Currently biologically-derived
products only account for 6% of all medicinal drugs on the market in Europe; however,
such products may play an increasingly large role as they account for a much larger share
of 40% of products in Phase III trials, and health related product innovation in SynBio
may further add to this trend (Salmikangas 2011).
A particularly challenging issue in this context is the way in which future (synthetic)
biologically-derived medicinal products may increasingly combine different – pharma-
cological as well as mechanical – modes of action, in which case there would be more
and more blurring of the boundaries between distinct regulatory regimes established in
Europe for drugs on the one hand, and medical devices on the other. To anticipate future
developments in the field of (synthetic) biologically derived products and to strengthen
the institutional preparedness of the EMA and other stakeholders in assessing these devel-
opments, the workshop found a clear need to reconsider the current distinction between
pharmaceuticals and devices in the process of medical product approval in Europe.
Other issues raised in the SYBHEL workshop discussions concerned processes of
translation for (future) SynBio-based experimental treatments as they move from the
laboratory to the clinic. Having patient access to experimental therapies that are ac-
tively moving through the translational stages required for formalizing treatments may
become a potential source of contention because of the interplay between commercial,
individual, public and scientific interests in developing SynBio health applications.
Moreover, clinical research needed to develop SynBio health technologies might entail
a degree of risk beyond that usually associated with other forms of experimental treat-
ment. Together these issues suggest a need to reconsider the ethical paradigms that
apply to clinical research and experimental treatment (Chan 2012). Especially import-
ant in this respect is a concern that was expressed in the European Policy Workshop
about the lack of transparency of the current system of ethical review of individual re-
search projects on the EU level. Thus, in order to support broader ethical reflection on
the challenges arising from the development of SynBio therapies and other emerging
health technologies, there is a need to consider a more transparent process of ethical
Douglas and Stemerding Life Sciences, Society and Policy 2014, 10:6 Page 10 of 18
http://www.lsspjournal.com/content/10/1/6review, in which the results of research ethics evaluations are not only fed back to
individual projects (as is the current practice within DG Research and Innovation),
but to wider communities of researchers, patients, ethicists and social scientists.Findings and recommendations concerning anticipatory governance of
SynBio innovation
Other important reflections arising from the interactions in the European Policy
Workshop pertained to the nature of SynBio as a science. Due to the fact that SynBio
is in an early research stage of development it therefore lacks clearly defined (health)
products to which established regulations might apply. Indeed, in several respects, the
field is still an ill-defined moving target. A special feature of SynBio is ‘cross-borderness’
(Zhang et al. 2011), or its combination of approaches from a variety of disciplines –
biology, engineering, physics, computer science, and chemistry. The field also involves
communities of young students attracted by the International Genetically Engineered
Machines (iGEM) competition in SynBio, as well as amateur Do-It-Yourself (DIY)Bio
or ‘garage’ SynBio communities. Cross-borderness implies new levels of complexity
and unfamiliarity, not only in terms of the phenomena studied and engineered in the
SynBio field, but also in terms of various disciplinary and cultural traditions crossing
each other, with their own norms, values, beliefs, and conventions with regards to risk.
In the face of future uncertainty and cross-borderness, we not only need adaptive
forms of government regulation, but also a flexible and evolving ‘art of governance’
involving the diversity of communities and stakeholders that are shaping the field
(Zhang et al. 2011).
Even more important is an anticipatory art of governance which takes into account
broader discourses of concern, involving deeply rooted convictions and values in society,
which may be more decisive for the future social acceptance of SynBio than the more
narrowly defined discourses of risk and regulation. In this context, one of the work-
shop presenters discussed experiences in the UK with a public SynBio dialogue, show-
ing that participants were not only concerned with risks and benefits of potential
future applications, but also with the motivations of actors and stakeholders shaping
the field, that is, the individual and societal goals and interests that drive research
(Bhattachary et al. 2010). Another aspect that was emphasized in the workshop discus-
sions is the need for a shift in focus in these broader discourses of concern from ‘hard’
impacts relating to tangible technological risks for human health and the environment,
to ‘soft’ impacts relating to the complex and often unintended ways in which technologies
may transform individual behaviours, public attitudes and values, social relationships, and
economic balances of power (Swierstra and te Molder 2012).
As was also pointed out in the European Policy Workshop, anticipatory governance
implies the creation of multiple opportunities for interaction between science and society
as a form of ‘extended interdisciplinarity’ (Calvert 2011). This notion implies, on the
one hand, engaging communities of researchers with the social and ethical ramifica-
tions of their work. On the other hand, it means involving a broad range of stake-
holders and publics with issues that relate to current practices and strategies of SynBio
research and innovation. In doing so, this interaction process actively distributes the
responsibility for the safe and fair development of SynBio practices and products;
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2011). Extended interdisciplinary is promoted by the European Commission in terms
of ‘responsible research and innovation’, with the aim to integrate and align societal
needs and demands more upstream in the technological development process (Von
Schomberg 2012 and Von Schomberg 2013; Owen et al. 2012). The recent European
call for Mobilisation and Mutual Learning Action Plans is a very interesting and signifi-
cant initiative in this respect. During the European Policy and Global Health Workshops
different options have been proposed that might be supported by the European Commis-
sion as experiments in anticipatory governance, involving SynBio researchers and a variety
of stakeholders and publics in mutual learning about the wider societal aims and concerns
in regard to SynBio (and human health)b. These recommendations concerning experi-
ments in anticipatory governance are summarized in Table 5 and described in more detail
below.SynBio road-mapping as a governance experiment supporting global health goals
Discussions in the Global Health Workshop focused on the ways in which SynBio might
address important problems and goals of global public health, as well as the conditions
needed to address such issues. One proposal at that workshop suggested that a road-
mapping exercise could be conducted for SynBio in global health (Johnson 2012), similar
to what has been seen in the case of information communication technologies and semi-
conductors (Schaller 2004). Such an exercise could be useful for setting short and longer
terms goals, identifying requirements needed for the technology to develop, and coordin-
ate concrete plans of action for the next ten to fifteen years. In doing so it might integrate
technical priorities with research agendas and policy priorities, and ensure that such
an infrastructure would be open, accessible and beneficial for all constructive interests
in SynBio.
The road-mapping exercise proposed by Johnson has some distinctive features com-
pared to the recently published SynBio roadmap for the UK (UK Synthetic BiologyTable 5 Findings and recommendations concerning anticipatory governance of SynBio
innovation
Type of anticipatory governance Recommendation
SynBio road-mapping for global health Organize an open process of community engagement of imaginative
thinking for researchers, industry, funding agencies, international
health and innovation policymaking organisations, NGOs and
representatives of end-users in the field of global public health. Goals
would be to outline technical priorities, but also integrating them with
research agendas and policy options, to ensure that such an
infrastructure would be open, accessible and beneficial for all
constructive interests in SynBio, thus stimulating pre-competitive
cooperation in the field.
Real-time TA Engage researchers and a wider circle of relevant stakeholders in an
interactive process of imaginative deliberation, considering options,




Develop ‘techno-moral’ scenarios as a tool to stimulate imagination,
reflection and debate in the context of real time TA, education and
public engagement activities.
Experiments with different approaches
to intellectual property
Seek to support initiatives from the research community and other
parties considering alternative IP regimes and reward structures in
SynBio and other fields (e.g. the Health Impact Fund).
Douglas and Stemerding Life Sciences, Society and Policy 2014, 10:6 Page 12 of 18
http://www.lsspjournal.com/content/10/1/6Roadmap Coordination Group 2012). The idea of a SynBio roadmap for global health
would be to stimulate pre-competitive cooperation in the field and, in doing so, not only
circumvent some of the challenges relating to the intellectual property protection of bio-
logical parts and processes but simultaneously act as a form of global governance
(Johnson 2012). Workshop participants noted that for it to have a chance of being suc-
cessful it would have to be underpinned by principles of transparency, responsibility and
accessibility, and as a result be developed in an open process of community engagement,
involving in a process of imaginative thinking, researchers, industry, funding agencies,
international health and innovation policymaking organisations, NGOs and representa-
tives of end-users in the field of global public health.
While the idea of a roadmap was broadly supported by Global Health Workshop
participants, it was clearly not accepted naively. Important considerations about the
heterogeneity of SynBio were stressed, which would have to be taken into account if
such an exercise were to be conducted. Arguably, a number of different approaches
exist for SynBio to contribute to global health (Douglas and Stemerding 2013a). One
SynBio researcher participating in the workshop presented a targeted approach in
which a specific disease with major global health impacts became the aim of a SynBio
funding initiative by the Grand Challenges for Global Health Explorations Grant
Program of the Bill and Melinda Gates Foundation (Vohra and Blakely 2013). An-
other and more generic perspective on addressing global health issues was offered by
one of our participants who sought the construction of fundamental multi-purpose
pathways in microbial cells, which may serve as platforms that can be tailored to
many kinds of applications, using advanced tools for computer-aided design of gen-
etic circuits (Carothers 2013).
Obviously a number of different elements would need to be considered in a road-
mapping exercise, and a number of questions remained in the workshop: i.e. who
would be involved, who would set its milestones, what matrixes – and underlining
values – would be used in evaluation of the milestones and of roadmap(s) more gener-
ally, what would be the intellectual property arrangements for any resulting products
or processes, would there be only one roadmap? The point here is not to set-out what
such an exercise would look like in practice, but rather to offer it as a possible way of
governing the development and practice of SynBio for human health. Interestingly,
the workshop participant from the OECD Working Party on Biotechnology sug-
gested that this organization might play a role in brokering such an activity. The
European Commission and especially the recently established ERA-Net in Synthetic
Biology could play a role as well.Real-time technology assessment as a governance experiment supporting responsible
SynBio innovation
Experiments in anticipatory governance might also include real-time technology as-
sessment (TA) initiatives (Guston and Sarewitz 2002), aiming at mutual learning
about challenges relating to the future societal embedding and impacts of potential
applications of synthetic biology. The focus of this TA approach is on the level of
SynBio research projects, like those funded by the Grand Challenges for Global
Health Explorations Grant Program or (health related) projects undertaken as part
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tion of future ‘application scenarios’ with the aim to engage researchers and a wider
circle of relevant stakeholders in an interactive process of imaginative deliberation,
considering options, needs, conditions and alternatives for future applications envisaged
in particular projects.
The iGEM community constitutes a particular interesting forum of young researchers
in which real-time TA experiments can be – and sometimes are – undertaken in the
Human Practice component of the competition. In their work teams of young re-
searchers develop and present proof-of-concept proposals for prospective SynBio appli-
cations in the areas of health, environment, food, fuels, and beyond. One of the central
components upon which proposals are judged is the degree to which it considers ‘Human
Practice’, or the kind of societal impact the prospective SynBio application might have on
social organization. This element of the iGEM competition urges participants to reflect on
how safety, security, ethics, ownership, sharing, and innovation elements of their prospect-
ive intervention will be integrated and received in communities outside of SynBio. In
doing so the Human Practice component of the competition asks its young researchers:
‘Will the world be a safe place if we make biology easy to engineer? How do the lessons of
the past inform the discussion going forward? Think beyond just convincing people that
“synthetic biology is good”. Find a new way to help human civilization consider, guide and
address the impacts of ongoing advances in biotechnology’ (iGEM 2012). Not only is a
special prize given to the ‘Best Human Practice Advance’, but the gold medal can also be
secured if a team ‘outlines and details a new approach to an issue of Human Practice’,
alongside the other key judging criteria.
Many of the projects presented at iGEM are associated with larger projects involving
senior researchers. While this association stands to benefit and facilitate the develop-
ment of some of the iGEM projects it also simultaneously creates interesting opportun-
ities to more firmly integrate real-time TA activities in the field of SynBio, thus
widening practices of responsible research and innovation. In the process researchers
that are new to the field are socialized into a culture of responsibility that facilitates
their reflection about the broader contexts into which their future research could be
based. Having this reflection take place concurrently with research itself is a key element
of real-time TA, and should be supported in this and other spheres of SynBio practice as a
positive and productive tool for governance.Development of scenarios as a governance experiment supporting future imagination
The development of ‘techno-moral’ scenarios as a tool to stimulate imagination, reflection,
debate, education, and public engagement has been proposed in the European Policy
Workshop as another way to support anticipatory governance in a highly uncertain
field. While application scenarios focus on the prospects and challenges for innovation
and related regulatory concerns, techno-moral scenarios highlight the wider trans-
formative potential of SynBio in society, thus shifting the attention to ‘soft’ impacts
(Swierstra et al. 2009; Boenink et al. 2010). Techno-moral scenarios invite audiences
to imagine and appraise ways in which imperfect technologies like SynBio health ap-
plications might change our world, our ideas, values and ideals. As thought experi-
ments techno-moral scenarios can be used to create a controlled environment for
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the underlying reasons, beliefs, values and concerns informing public debates about
new and emerging science and technology (Calladine and Newson 2011).
Scenario studies are increasingly being used in the area of SynBio (Aldrich et al.
2008), and have recently been used by British social scientists who were commissioned
by the Biotechnology and Biological Sciences Research Council in the UK to provide a
set of tools to engage with the public on issues relating to sustainable bioenergy (Dingwall
et al. 2011) that interestingly contains a scenario relating to SynBio. Further, the European
Patent Office also conducted a large-scale scenario study into how the patent system may
be transformed in the near future due to a variety of challenges, which included a scenario
on cumulative technologies like SynBio (European Patent Office 2011). Each of these ap-
proaches to scenarios studies offers their own particular approach, and target different
goals (i.e. reflect on possible changes in values, facilitate public engagement, or anticipate
institutional transformation). Nevertheless, these approaches all represent experiments
that facilitate imaginative future thinking that can be deployed as a mechanism of govern-
ance that seeks to facilitate positive technological development rather than those that at-
tempt to contain future risks.Governance experiments supporting different approaches to intellectual property
Issues relating to intellectual property play centrally in both the policy documents out-
lined in our introduction, and in much of the social science research on SynBio that
includes a special issue in the journal BioSocieties entirely dedicated to the topic. In
their guest editorial Pottage and Marris (2012) stress the importance of not seeing this
discourse as a ‘simple dichotomy between open source and patenting strategies’, and
instead advocate for social science work into the ‘concomitant engineering of IP and
life sciences’. If we accept this view, then governance question becomes: how do we
capitalize on the intersections of open source and patenting approaches, as well as the
co-production between law and biology, so as to steer SynBio in a positive and pro-
ductive way?
Throughout our two workshops we found that members of the SynBio research com-
munity support the development of a technical infrastructure that is open, accessible
and beneficial for all constructive interests in the field. However, as pointed out in one
of the other work-package workshops of the SYBHEL project (de Miguel Beriain 2011
and de Miguel Beriain 2012), an important and controversial question still remains: to
what extent is it possible to create a robust open access system in a field in which it will
be very costly to develop marketable innovations? From our Global Health Workshop
we learned that SynBio researchers who favour free access to knowledge relevant for glo-
bal health are facing institutional pressures from their university to pursue IP protection.
Given the international IP debate – as discussed for example in the Future Scenarios re-
port of the European Patent Office (European Patent Office 2011) – there is a clear need
for flexibility and room to manoeuvre when it comes to IP and patenting for cumulative
technologies like SynBio.
As a consequence, experiments with different approaches to IP may function as positive
and productive form of governance. For instance, the OECD (2011) recently published a
report on collaborative mechanisms for IP management in the life sciences in which they
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one of the most notable SynBio applications for global health – i.e. synthetic Artemisinin
to combat malaria – has been developed on the basis of such a collaborative arrangement
(Douglas and Stemerding 2013b). Another experiment related to IP and public health
innovation, that was discussed during the Global Health Workshop, was the proposal
for a Health Impact Fund (Hollis 2013). The Health Impact Fund leaves the protection
and reward components of the patent system intact, and ensures remuneration for the
innovators of effective public health interventions for ten years; however, the health
interventions themselves are made widely available at cost (Hollis 2008; Hollis and
Pogge 2008).Conclusion: Achieving policy-relevance in the area of SynBio
In this article we have described how we have shifted our focus in ‘doing ELSI’ over the
course of the SYBHEL project. We moved from potential future implications of SynBio
for human health as our primary governance concern, to issues of government regulation
and anticipatory governance more immediately relating to current practices and experi-
ences in the field. In doing so, our final policy recommendations took the forms that more
closely resemble Tables 4 and 5, rather than Tables 2 and 3. This shift in focus is not only
relevant in addressing policymaking institutions, but also suggests a need to reconsider
established ways of understanding the ethical, legal and social implications of new and
emerging science and technology. ELSI research is strongly predicated by a concern to
protect society against harmful implications of science and technology and thus repro-
duces a long-standing division of labour in our society between promoters of new
technology and critical responders (Garud and Ahlstrom 1997). In this light, our rec-
ommendations for experiments in anticipatory governance imply a move in ELSI re-
search towards a less antagonistic stance, contributing in a critical as well as
collaborative way to discussions on how – and under what conditions – SynBio might
address important problems and goals of human and global public health. The Global
Health Workshop that we organized through our SYBHEL work was a most inspiring
event in this respect because it clearly showed how the aim of responsible research
and innovation might be defined by a common pursuit for the ‘right impacts’. In en-
gaging with a variety of actors related to the research, development, and deployment
of SynBio health products, and in constructively reflecting on our own practices of
doing so, we have sought to bridge the gap between innovation and ELSI and to pro-
duce recommendations that reflect challenges relevant to current practices (yet not
limited to the research phases), which are at the same time relevant to – and action-
able for – policymakers.Endnotes
aThis was the case despite specific examples of how the way SynBio raised ELSI
issue: e.g. horizontal gene transfer from accidental release of engineered bacteria or
viruses is a specific bio-safety concern of SynBio health products, synthetically atten-
uated virus engineering (SAVE) presents real dual-use and bio-security issues, overly
narrow or broad patents on essential SynBio building block might stifles health
innovation are tangible intellectual property problems, and human enhancement &
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engineering -human- life.
bSeveral of the experiments that have been suggested in our workshop discussions
have been included in the programme of activities that will be carried out in the next
four years by participants of SYNENERGENE, a European FP7 Mobilisation and Mutual
Learning Action Plan in the field of synthetic biologie: http://www.synenergene.eu/.
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